Stereotactic Body Radiation Therapy in the Management of Oligometastatic Uterine Cancer
Limited data exist for the use of stereotactic body radiotherapy (SBRT) in oligometastatic uterine cancer. We aimed to evaluate the outcomes of using SBRT for treating oligometastatic uterine cancer. This is a single-institute retrospective study evaluating the use of SBRT in patients with oligometastatic uterine cancer. Survival Endpoints were analyzed using the Kaplan-Meier method. Twenty-three uterine cancer cases with 24 oligometastatic sites were identified, who received SBRT to metastatic sites between 2011 and 2022. The median follow-up period was 30 months (IQR 14-63). The median SBRT dose, fractions, and BED10 were 42 Gy (IQR: 35-45), 5 fx (IQR: 5-5), and 77 Gy (IQR: 60-86). The median time for reirradiation was 30 months (IQR 14-81). Nodal recurrences in 58% of cases were the most common site for SBRT use. The 6-month, 1-, and 2-year local control was 87%, 83%, and 77%, and locoregional control was 83%, 69%, and 64%, respectively. Acute toxicities were observed in 50% of cases with 42% of grade 1 fatigue. Late toxicities were observed in two cases (8%) of grade 2 bowel toxicity. No grade 3 or higher toxicity. SBRT is a safe and effective tool for the management of oligometastatic uterine cancer.